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Abstract
AIM: To investigate the association between autoim-
mune pancreatitis (AIP) and systemic autoimmune dis-
eases (SAIDs) by measurement of serum immunoglobu-
lin G4 (IgG4).
METHODS: The serum level of IgG4 was measured 
in 61 patients with SAIDs of different types who had 
not yet participated in glucocorticosteroid treatment. 
Patients with an elevated IgG4 level were examined by 
abdominal ultrasonography (US) and, in some cases, by 
computer tomography (CT).
RESULTS: Elevated serum IgG4 levels (919 ± 996 mg/
L) were detected in 17 (28%) of the 61 SAID patients. 
10 patients had Sjögren’s syndrome (SS) (IgG4:� 590 ± 
232 mg/L), 2 of them in association with Hashimoto’s 
thyroiditis, and 7 patients (IgG4:� 1388 ± 985.5 mg/L) 
had systemic lupus erythematosus (SLE). The IgG4 lev-
el in the SLE patients and that in patients with SS were 
not significantly different from that in AIP patients (783 
± 522 mg/L). Abdominal US and CT did not reveal any 
characteristic features of AIP among the SAID patients 
with an elevated IgG4 level.
CONCLUSION: The serum IgG4 level may be elevated 
in SAIDs without the presence of AIP. The determina-
tion of serum IgG4 does not seem to be suitable for 
the differentiation between IgG4-related diseases and 
SAIDs.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is an increasingly recog-
nized type of  chronic pancreatitis that is clearly distinct 
from other types of  chronic pancreatitis. It is character-
ized by its morphology, immunologic features, pathology 
and glucocorticosteroid responsiveness[1-4].
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Immunological examinations in AIP patients have de-
monstrated high incidences of  hypergammaglobulinemia 
(43%), increased serum levels of  immunoglobulin G (IgG) 
(62%-80%) and IgG4 (68%-92%), and the presence of  
antinuclear antibodies (40%-64%) and rheumatoid factor 
(25%). Among all the serological diagnostic features, an 
elevated serum level of  IgG4 has the highest individual 
diagnostic value; however, it is not disease specific. Fur-
thermore, an elevated serum IgG4 level correlates with 
the activity of  AIP[5,6]. Kamisawa et al[7] reported an as-
sociation between serum IgG4 level and extrapancreatic 
lesions in patients with AIP. AIP patients with a serum 
IgG4 level ≥ 2200 mg/L frequently exhibit extrapancre-
atic lesions.
The immunologic and histologic features of  AIP and 
the glucocorticosteroid responsiveness suggest an auto-
immune mechanism for the development of  the disease[8]. 
AIP is accompanied by other autoimmune diseases (scle-
rosing cholangitis, sclerosing sialadenitis, retroperitoneal 
fibrosis, enlarged celiac and hilar lymph nodes, chronic 
thyroiditis and interstitial nephritis, etc.) in 50%-63% of  
cases, suggesting that AIP may be a systemic disorder[1-4]. 
The occurrence of  autoimmune diseases in association 
with AIP is well documented[9,10], but the incidence of  
such associations has not been reported.
The aim of  the present study was to assess the pres-
ence of  AIP in different systemic autoimmune diseases 
(SAIDs) through measurement of  the serum IgG4 level 
and examination of  the morphology of  the pancreas.
MATERIALS AND METHODS
Patients and diagnosis of diseases
Serum samples were obtained from 61 patients with dif-
ferent SAIDs who had been admitted to our Department 
of  Rheumatology and had not participated in glucocor-
ticosteroid treatment during the past 2 years. One male 
and 60 females (mean age 54.5 years, range 29-82 years) 
were recruited.
Autoimmune diseases were diagnosed according to 
standard diagnostic criteria[11-14]. The diagnosis of  AIP 
was based on the HISORt criteria[15]. The most frequent 
diagnosis was Sjögren’s syndrome (SS), but systemic lu-
pus erythematosus (SLE), Hashimoto thyroiditis, Rayn-
aud’s syndrome, polymyositis and systemic sclerosis also 
occurred (Table 1).
Serum samples were additionally obtained from 7 age- 
and sex-matched healthy subjects, and 6 patients with 
AIP. In one AIP patient, the AIP was accompanied by 
rheumatoid arthritis and ankylosing spondylitis.
All participants provided their written informed con-
sent. The study protocol was approved by the ethics com-
mittee at the University of  Szeged and was carried out 
in full accordance with the most recent revisions of  the 
Helsinki Declaration.
IgG4 assay
After collection, serum samples were stored at -70 ℃ until 
analyzed. The IgG4 subclass was determined by the ra-
dial immunodiffusion (RID) method (The Binding Site 
Limited, Birmingham, United Kingdom). The diameters 
of  precipitation rings were measured after 72 h. The re-
sults were read using the RID reference table. The low-
est detection limit was 22.4 mg/L. The intra- and inter-
assay coefficients of  variation were 3.26 and 0.89 CV%, 
respectively, as stated by the manufacturer. A cutoff  value 
of  400 mg/L was employed.
Patients with a serum IgG4 level of  > 400 mg/L were 
examined by a gastroenterologist. The clinical and labora-
tory data were reviewed and abdominal ultrasonography 
(US) and computed tomography (CT) were performed. 
Anti-SS-A/SS-B autoantibody determination
The presence of  anti-SS-A/SS-B autoantibodies was de-
termined by means of  commercial enzyme-linked immu-
nosorbent assays, conducted according to the protocols 
provided by the manufacturers.
Experimental data were evaluated statistically with 
the independent-samples t test. P-values < 0.05 were ac-
cepted as being statistically significant. Statistical data is 
expressed as mean ± SD.
RESULTS
An elevated serum IgG4 level (mean value 919 ± 996 
mg/L) was detected in 17 (28%) of  the 61 SAID patients 
(Figure 1). Ten of  the 17 patients had SS (mean serum 
IgG4 590 ± 232 mg/L) (2 cases were associated with 
Hashimoto’s thyroiditis), 7 (mean serum IgG4 1388 ± 
985.5 mg/L) were diagnosed with SLE. Two SLE patients 
showed markedly elevated IgG4 levels (> 3000 mg/L). In 
Table 1  Distribution of gender and age in groups of patients
No. of 
patients
Male/
female
Age 
mean (range)
Sjögren's syndrome 35 1/34 56.7 (29-82)
Systemic lupus erythematosus 22 0/22 50.2 (31-68)
Systemic sclerosis  4 0/4 59.5 (45-80)
Normal subjects  7 4/3     68 (56-80)
Autoimmune pancreatitis  6 3/3 53.7 (27-75)
Sjögren's syndrome
Systemic lupus erythematosus
Systemic sclerosis
Autoimmune pancreatitis
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Figure 1  Serum immunoglobulin G4 levels in different systemic autoimmune 
diseases and autoimmune pancreatitis. Dotted line: Cutoff value (400 mg/L).
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one case, SLE was associated with Raynaud’s syndrome, 
while the other patient suffered from xerophtalmia and 
bronchial asthma. The serum IgG4 level was elevated 
(mean serum IgG4 783 ± 522 mg/L) in 5 (83%) of  the 6 
AIP patients. The patient with a normal level of  IgG4 had 
typical pancreatic histology and his condition improved 
with steroid therapy. The IgG4 levels in these SLE and SS 
patients were not significantly different from that in the 
AIP patients.
US examination revealed a normal pancreas in 11 of  
the 17 SAID patients with elevated serum IgG4 levels, but 
raised the suspicion of  AIP by demonstrating a gracile 
pancreas in 2 cases (both suffered from SS), and widen-
ing of  the body or the tail of  pancreas, each in a further 
one patient (both suffered from SLE). However, in none 
of  these 4 cases was AIP confirmed by an abdominal CT 
scan. The US examinations indicated pancreatic steatosis 
in 2 additional cases. None of  the SAID patients had pan-
creatic duct dilatation.
The presence of  anti-SS-A/SS-B autoantibodies and 
the potential relation of  this to an elevated IgG4 level 
were examined in the patients with SS. Both anti-SS-
A-positivity and anti-SS-B-positivity was detected in 22 
patients; 7 of  them exhibited an elevated IgG4 level. The 
anti-SS-A was positive and the anti-SS-B was negative 
in 9 cases; 2 of  these patients had a high IgG4 level. In 
4 patients with SS, neither anti-SS-A-positivity, nor anti-
SS-B-positivity was found; an elevated IgG4 level was 
detected in only one of  these cases.
DISCUSSION
The present study has demonstrated that the serum IgG4 
level may be elevated in SAIDs, without the presence of  
AIP.
AIP can be complicated by a variety of  extrapan-
creatic lesions, which appear synchronously or meta-
chronously with the pancreatic lesion, share the same 
pathological conditions, and show a favorable response 
to glucocorticosteroid therapy, characteristics indicative 
of  a common pathophysiological background. Among 
the variety of  extrapancreatic diseases, lachrymal and sali-
vary gland lesions are some of  the most frequent, found 
in 23%-39% of  patients with AIP[16,17]. Extrapancreatic 
lesions may mimic or be misdiagnosed as primary lesions 
of  the corresponding organs, e.g., lachrymal and salivary 
gland lesions for SS. It is therefore necessary to differen-
tiate between IgG4-related diseases and inherent diseases 
of  the corresponding organ. When the pancreatic lesion 
is obscured, it may be difficult to detect these presumably 
IgG4-related extrapancreatic lesions[4]. 
IgG4 is the rarest of  the 4 IgG subclasses in humans, 
with an incidence of  about 4%. IgG antibodies are pre-
dominantly involved in the secondary immune response; 
complement activation is possibly their most important 
biological function. The main role of  IgG4 is presumably 
to protect against the biological effects of  the comple-
ment-fixing IgG subclasses and to act in parasitic infesta-
tion or various forms of  atopy[18-20]. Serum IgG4 levels 
are frequently and significantly elevated in AIP patients[6] 
and an elevated level of  serum IgG4 has been included 
among the laboratory criteria for the diagnosis of  AIP[4,15]. 
AIP patients with 3 extrapancreatic lesions have been 
reported to have significantly higher IgG4 levels than 
those lacking such lesions[16]. The optimal cutoff  value for 
discriminating AIP patients with extrapancreatic lesions 
from those without was demonstrated on the basis of  re-
ceiver operator characteristic curves to be 2200 mg/L[7].
The serum IgG4 level was measured in 61 SAID pa-
tients in our study, 28% of  whom proved to have an ele-
vated serum level of  IgG4. However, none of  them could 
be diagnosed with AIP according to the HISORt criteria. 
What could be the reason for this?
One explanation is the composition of  our patient 
cohort. In Japan AIP predominantly affects men, with a 
male:female ratio of  2.85:1[16]. Moreover, there was a male 
preponderance in the United Kingdom, European and US 
studies (100%, 66% and 65% male, respectively), similar 
to in reports from Japan[21-24]. In contrast, there was only 
one male in our patient population.
Lachrymal and salivary lesions associated with AIP 
were previously considered to be complications of  SS. 
However, in contrast to those accompanying SS, the lach-
rymal and salivary gland lesions associated with AIP yield 
negative results for anti-SS-A/SS-B autoantibodies and 
show numerous IgG4-positive plasma cell infiltrations in 
the affected tissues. These lesions are currently thought 
to correspond to Mikulicz’s disease[25]. The explanation 
for our negative results may be that there was only one 
patient with negative SS-A/SS-B autoantibodies in our 
study group. 
Another point is that autoantibodies against FcεRIα 
are detected in the sera of  patients with different autoim-
mune diseases (such as SLE, dermatomyositis, pemphigus 
and pemphigoid); these antibodies are from subclasses 
IgG2 and IgG4, but they are functionally inactive[26]. In 
our study, elevated IgG4 levels were found in 7 patients 
treated for SLE. 
Moreover, our 17 SAID patients with elevated IgG4 
levels included 6 who suffered from different concomi-
tant diseases which could cause the increase in the serum 
level of  IgG4. In one patient, nodular sclerosis Hodgkin 
lymphoma (HL) was diagnosed histologically. HL cells 
frequently express interleukin 13 (IL-13) and its receptor. 
Besides exerting several effects on B cells (e.g., promot-
ing their survival and proliferation), IL-13 switches the Ig 
class to IgG4 and IgE[27]. In another patient, bullous pem-
phigoid was identified, which is among the most common 
blistering autoimmune skin lesions. One of  the features 
of  the disease is the presence of  autoantibodies against 
hemidesmosomal antigens (i.e., bullous pemphigoid an-
tigen 1 and 2) in the serum and in affected areas of  the 
skin. The major types of  these autoantibodies are IgG4 
and IgE[28]. In a third patient, cutaneous lymphocytic vas-
culitis was diagnosed, which could also explain the serum 
IgG4 elevation[29]. In 2 patients, the underlying disease 
was accompanied by Hashimoto’s thyroiditis, which can 
elevate the IgG4 level since thyroglobulin autoantibodies 
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are from subclasses IgG2 and IgG4[30]. There was also one 
patient with bronchial asthma, in which disease elevated 
titers of  IgG4 can be found[31].
Finally, SS was diagnosed in the remaining 4 patients, 
one of  whom was seronegative, while the others were se-
ropositive. The elevated serum IgG4 level in patients with 
seronegative SS may possibly be explained by the pres-
ence of  Mikulicz’s disease[32]. Furthermore, an elevated 
serum IgG4 level has also been reported in SS[33].
However, not all AIP patients display elevated serum 
IgG and IgG4 levels. IgG4-negative AIP patients seem to 
occur more frequently in Europe[34]. Furthermore, some 
AIP cases improve spontaneously[4]. Hence, it cannot be 
ruled out that our SAID cohort included AIP patients 
who were not diagnosed by the measurement of  serum 
IgG4 or in whom the morphology of  the pancreas had 
already normalized by the time of  our examination.
Overall, it can be concluded that the serum IgG4 level 
may be elevated in SAIDs, but as a consequence of  the 
concomitant SAID rather than of  AIP. The determina-
tion of  serum IgG4 does not seem to be suitable for the 
differentiation between IgG4-related diseases and SAIDs.
COMMENTS
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